Fig. 3
Quantification of angiogenic activities in the CAM assay. a. A schematic diagram of treatment with Bevacizumab in the CAM assay. The filter paper soaked with phosphate-buffered saline (PBS) containing Bevacizumab was placed near the graft on embryonic development day (EDD) 12 and the transplant site was observed two days later. b. Macroscopic images from the bottom side. Bevacizumab inhibited tumor angiogenesis. Lower and upper panels show CAMs with and without transplantation. Pictures were captured at 1.5 × magnification. Blue arrowheads indicate the blood vessels that we measured. Blood vessels marked with “※” were preexisting vessels and were excluded from the measurements. c. Dot plots of the vessel area (mm2) and mass area (mm2) measured by Image J. Bevacizumab reduced the vessel area. The left graph shows the vessel area. The right graph shows the mass area. Non-treatment; n = 7, Bevacizumab; n = 9. Mean values ± SE, unpaired t test, **P < 0.01. d. Hematoxylin and eosin (HE) staining is shown on EDD 14. The part surrounded by the red dotted line is the graft. Scale bars: 100 μm